- Home
- EXEL vs BAX Comparison
EXEL vs BAX Comparison
Compare EXEL & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- BAX
- Stock Information
- Founded
- EXEL 1994
- BAX 1931
- Country
- EXEL United States
- BAX United States
- Employees
- EXEL N/A
- BAX N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- BAX Medical/Dental Instruments
- Sector
- EXEL Health Care
- BAX Health Care
- Exchange
- EXEL Nasdaq
- BAX Nasdaq
- Market Cap
- EXEL 10.4B
- BAX 11.3B
- IPO Year
- EXEL 2000
- BAX N/A
- Fundamental
- Price
- EXEL $38.94
- BAX $19.16
- Analyst Decision
- EXEL Buy
- BAX Hold
- Analyst Count
- EXEL 22
- BAX 9
- Target Price
- EXEL $44.10
- BAX $30.78
- AVG Volume (30 Days)
- EXEL 2.9M
- BAX 6.4M
- Earning Date
- EXEL 11-04-2025
- BAX 10-30-2025
- Dividend Yield
- EXEL N/A
- BAX 3.55%
- EPS Growth
- EXEL 81.76
- BAX N/A
- EPS
- EXEL 2.08
- BAX N/A
- Revenue
- EXEL $2,230,005,000.00
- BAX $11,023,000,000.00
- Revenue This Year
- EXEL $9.14
- BAX $7.40
- Revenue Next Year
- EXEL $12.59
- BAX $3.78
- P/E Ratio
- EXEL $18.75
- BAX N/A
- Revenue Growth
- EXEL 10.73
- BAX 3.90
- 52 Week Low
- EXEL $31.18
- BAX $18.42
- 52 Week High
- EXEL $49.62
- BAX $37.74
- Technical
- Relative Strength Index (RSI)
- EXEL 50.54
- BAX 23.22
- Support Level
- EXEL $33.76
- BAX $22.53
- Resistance Level
- EXEL $40.63
- BAX $23.35
- Average True Range (ATR)
- EXEL 1.30
- BAX 0.62
- MACD
- EXEL 0.17
- BAX -0.19
- Stochastic Oscillator
- EXEL 75.47
- BAX 14.29
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.